Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TET2 |
Variant | P929Lfs*24 |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | TET2 P929Lfs*24 indicates a shift in the reading frame starting at amino acid 929 and terminating 24 residues downstream causing a premature truncation of the 2002 amino acid Tet2 protein (UniProt.org). P929Lfs*24 has not been characterized however, due to the effects of other truncation mutations downstream of P929 (PMID: 24994606), is predicted to lead to a loss of Tet2 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
TET2 mutant TET2 inact mut TET2 P929Lfs*24 |
Transcript | NM_001127208.3 |
gDNA | chr4:g.105236728delC |
cDNA | c.2786delC |
Protein | p.P929Lfs*24 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_024454103.2 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
NM_017628.4 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
XM_006714242.3 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
XM_017008319.1 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
XM_024454102.2 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
XM_024454103.1 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
XM_047415839.1 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
XM_005263082.4 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
XM_047415842.1 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
XM_024454102.1 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
NM_001127208.2 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
NM_017628.4 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
XM_006714242.4 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
XM_005263082.3 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
XM_047415843.1 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
NM_001127208.3 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
XM_047415841.1 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
XM_047415840.1 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
XM_017008319.2 | chr4:g.105236728delC | c.2786delC | p.P929Lfs*24 | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|